270 reports of this reaction
2.6% of all POTASSIUM CITRATE reports
#6 most reported adverse reaction
NEPHROLITHIASIS is the #6 most commonly reported adverse reaction for POTASSIUM CITRATE, manufactured by Mission Pharmacal Company. There are 270 FDA adverse event reports linking POTASSIUM CITRATE to NEPHROLITHIASIS. This represents approximately 2.6% of all 10,334 adverse event reports for this drug.
Patients taking POTASSIUM CITRATE who experience nephrolithiasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEPHROLITHIASIS is a less commonly reported adverse event for POTASSIUM CITRATE, but still significant enough to appear in the safety profile.
In addition to nephrolithiasis, the following adverse reactions have been reported for POTASSIUM CITRATE:
The following drugs have also been linked to nephrolithiasis in FDA adverse event reports:
NEPHROLITHIASIS has been reported as an adverse event in 270 FDA reports for POTASSIUM CITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEPHROLITHIASIS accounts for approximately 2.6% of all adverse event reports for POTASSIUM CITRATE, making it a notable side effect.
If you experience nephrolithiasis while taking POTASSIUM CITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.